NEW YORK (GenomeWeb) – Cellectis today announced it has established a new subsidiary in New York to serve as the Paris-based firm's US headquarters. Cellectis, Inc. will feature laboratory space to develop engineered chimeric antigen receptor (CAR) T cells for gene editing-based cancer therapy.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

CNN reports that researchers have tied a new variant to opioid addiction risk.

Organoids derived from patients' tumors may help determine what chemotherapy treatment patients would benefit from, according to New Scientist.

An initiative from GenomeAsia 100K hopes to increase the number of South Asians in genetic research, according to NBC News.

In Science this week: genomic analysis of ancient and modern horses indicates population turnover, and more.